Earnings call transcript: Novartis Q3 2025 sees robust growth in sales and innovation
PositiveFinancial Markets

Novartis reported strong growth in its Q3 2025 earnings call, highlighting significant increases in sales and a commitment to innovation. This positive performance not only reflects the company's effective strategies but also positions it well in the competitive pharmaceutical market, showcasing its ability to adapt and thrive.
— Curated by the World Pulse Now AI Editorial System







